Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT)

Journal of Association of Physicians of India

Volumn 61, Issue 7, 2013, Pages 448-453

  Kalra, Sanjay ^a   Vithalani, Manoj ^b   Gulati, Gurjeet ^c   Kulkarni, C M ^d   Kadam, Yogesh ^e   Pallivathukkal, James ^f   Das, Brahmananda ^g   Sahay, Rakesh ^h   Modi, K D ⁱ  

^a BHARTI HOSPITAL   (India)

^b Medisurge Hospital   (India)

^c Paras Hospitals   (India)

^d Shrey Nursing Home   (India)

^e B J MEDICAL COLLEGE   (India)

^f MBBM Hospital   (India)

^g Cuttack Medical College   (India)

^h OSMANIA MEDICAL COLLEGE   (India)

ⁱ Modi Diabetic Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DYSLIPIDEMIA; FATTY LIVER; FEMALE; HUMAN; HYPERTENSION; INDIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; RISK FACTOR; SEX DIFFERENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FATTY LIVER; FEMALE; HUMANS; HYPERTENSION; INDIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RISK FACTORS; SEX FACTORS;

EID: 84880024479     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Farrell GC, Larter CZ. Nonalcoholic Fatty Liver Disease: from Steatosis to cirrhosis. Hepatology 2006;43:S00-S112.
2. Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, Lindor K.; Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005;41:64-71.
3. Farrell GC, Larter CZ. Nonalcoholic Fatty Liver Disease: from Steatosis to cirrhosis. Hepatology 2006;43:S00-S112.
4. Lazo M, Clark JM., The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28:39-50.
5. Bellentani S, Scaglioni F, Marino M, Bedogni G., Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155-61.
6. Duseja A., Nonalcoholic fatty liver disease in India-a lot done, yet more required. Indian J Gastroenterol 2010;29:217-25.
7. Singh SP, Nayak S, Swain M, et al. Prevalence of non alcoholic fatty liver disease in coastal eastern India: A preliminary ultrsonographic survey. Trop Gastroenterol 2004;25:76-9.
8. Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004;19:854-858
9. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, et al, Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007;6:161-3.
10. Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009;84:84-91.
11. Uchil D, Pipalia D, Chawla M, Patel R, Maniar S, Narayani, Juneja A. Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome. J Assoc Physicians India 2009;57:201-4.
12. Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 2009;57:205-10.
13. McCullough AJ. Thiazolidinediones for nonalcoholic steatohepatitis-promising but not ready for prime time. N Engl J Med 2006;355:2361-3.
14. Bugianesi E, Vanni E, Marchesini G, NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes, Current Diabetes Reports 2007;7:175-80.
15. Collantes R, Ong JP, Younossi ZM, Nonalcoholic fatty liver disease and the epidemic of obesity, Cleveland. Clin J Med 2004;71:657-64.
16. Cusi K., Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2009;16:141-9.
17. Tolman KG, Fonseca V, Tan MH, Dalpiaz A., Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 2004;141:946-56.
18. Angulo P, Keach JC, Batts KP, Lindor KD, Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
19. Younossi ZM, Gramlich T, Matteoni CA, et al., Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-5.
20. Ferreira VS, Pernambuco RB, Lopes EP, Morais CN, Rodrigues MC, Arruda MJ, et al., Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol 2010;54:362-8
21. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-967.
22. Yildirim B, Ozugurlu F, Sahin S, Ozyurt H, Atis O, Akbas A, et al., Association between elevated aminotransferase levels and the metabolic syndrome in Northern Turkey. Ann Hepatol 2010;9:161-5
23. Elizabeth H Harris. Elevated liver function tests in Type 2 Diabetes. Clinical Diabetes 2005;23:115-9.
24. West J, Brousil J, Gazis A, Jackson L, Mansell P, Bennett A. et al., Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus. QJM 2006;99:871-6.
25. Meybodi MA, Afkhami-Ardekani M, Rashidi M., Prevalence of abnormal serum alanine aminotransferase levels in type 2 diabetic patients in Iran. Pak J Biol Sci 2008;11:2274-7.
26. Judi L, Toukan A, Khader Y, Ajlouni K, Khatib MA., Prevalence of elevated hepatic transaminases among Jordanian patients with type 2 diabetes mellitus. Ann Saudi Med 2010;30:25-32.
27. Esteghamati A, Jamali A, Khalilzadeh O, Noshad S, Khalili M, Zandieh A. et al., Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. Diabetol Metab Syndr 2010;2:65.
28. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006;43:1145-51.
29. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:1212-8.
30. Lautämaki R, Borra R, Iozzo P, Komu M, Lehtimaki T, Salmi M, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Enddocrinol Metab 2006;291:E282-90.
31. Targher G, Bertolini L, Rodella S, Zoppin G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008;51:444-50.
32. Gunter, EW, Lewis, BG, Koncikowski, SM. Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. US Department of Health and Human Services, Center for Disease Control and Prevention, National Center for Environmental Health, National Center for Health Statistics: Atlanta, GA, 1996
33. Amrapukar DN, Amrapukar A. Non-alcoholic steatohepatitis clinicopathological profile. JAPI 2000;48:311-3.
34. http://www.nfhsindia.org/nutrition_report_for_website_18sep09.pdf
35. Duseja A, Das A, Das R, et al. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the west. Dig Dis Sci 2007;52:2368-74.
36. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, et al; on behalf of the Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011;34:1139-1144.
37. G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
38. Angelico F, Del Ben M, Conti R, et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 2003;18:588-94.
39. Rosen F, Roberts NR, Nichol CA. Glucocorticosteroids and transaminase activity: Increased activity of glutamic pyruvic transaminase in four conditions associated with gluconeogenesis. J Biol Chem 1959;476:80.
40. Westerbacka J, Cornér A, Tiikkainen M, Tamminen M, Vehkavaara S, Häkkinen AM, et al. Women and men have similar amounts of liver and intraabdominal fat, despite more subcutaneous fat in women: Implications of sex differences in markers of cardiovascular risks. Diabetologia 2004;47:1360-9
41. Kim HC, Jee SH, Han KH. Normal serum aminotransferase concentration and risk of mortality from liver disease: Prospective cohort study. Br Med J 2004;328:983-7
42. Pratt DS, Kaplan MM, et al. Evaluation of abnormal liver enzymes results in asymptomatic patients. New England Journal of Medicine 2000;342:1266-1271.
43. Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine transaminase levels in obese patients and patients with type 2 diabetes. Am J Med 2000;109:588-590.
44. Marchesini G, Brizi M, Morselli-Labate A, Blanchi G, Bugianesi E, McCullogh A, Forlani G, Melachionda N. Association of nonalcoholic fatty liver disease and insulin resistance. Am J Med 1999;107:450-5.
45. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009;41:615-25.
46. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
47. Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004;53:1020-1023.
48. Hsiao P, Kuo K, Shin S, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol 2007;22:2118-2123.
49. Day CP, James OF. Steatohepatitis: a tale of two 'hits'? Gastroenterology 1998;114:842-845.
50. Naniwadekar AS, Nutritional Recommendations for Patients with Non-Alcoholic Fatty Liver Disease:An Evidence Based Review. Pract Gastroenterol 2010;34:8-16.
51. Harrison SA, Fincke C, Helinski D, et al: A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623-628.
52. Hatzitolios A, Savopoulos C, Lazaraki G, et al: Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004;23:131-134.
53. Sabuncu T, Nazligul Y, Karaoglanoglu M, et al: The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with nonalcoholic steatohepatitis. Rom J Gastroenterol 2003;12:189-192.
54. Zelber-Sagi S, Kessler A, Brazowsky E, et al: A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-4.
55. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44.
56. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-4
57. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:200-6.
58. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.